Holen Sie sich die Stockscreener-App
5.85
4.10%
-0.25
Schlusskurs vom Vortag:
$6.10
Offen:
$6.06
24-Stunden-Volumen:
1.01M
Relative Volume:
0.81
Marktkapitalisierung:
$518.76M
Einnahmen:
$73.48M
Nettoeinkommen (Verlust:
$-108.30M
KGV:
-2.60
EPS:
-2.25
Netto-Cashflow:
$-67.17M
1W Leistung:
+11.64%
1M Leistung:
+28.01%
6M Leistung:
+53.14%
1J Leistung:
+2.09%
1-Tages-Spanne:
$5.68
$6.06
1-Wochen-Bereich:
$5.21
$6.255
52-Wochen-Spanne:
$2.8262
$7.79
Personalis Inc Stock (PSNL) Company Profile
Firmenname
Personalis Inc
Sektor
Branche
Telefon
650-752-1300
Adresse
6600 DUMBARTON CIRCLE, FREMONT, CA
Vergleichen Sie PSNL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
5.85 | 477.97M | 73.48M | -108.30M | -67.17M | -2.25 |
|
TMO
Thermo Fisher Scientific Inc
|
479.46 | 179.95B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
190.05 | 137.90B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
641.14 | 51.04B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
123.24 | 35.19B | 6.79B | 1.22B | 1.09B | 4.26 |
|
IQV
Iqvia Holdings Inc
|
187.22 | 31.26B | 15.70B | 1.24B | 2.01B | 6.91 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-15 | Eingeleitet | Guggenheim | Buy |
| 2025-03-17 | Eingeleitet | Craig Hallum | Buy |
| 2023-02-06 | Hochstufung | Needham | Hold → Buy |
| 2022-01-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-11-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-03 | Herabstufung | Needham | Buy → Hold |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-20 | Bestätigt | Needham | Buy |
| 2021-05-06 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-12 | Bestätigt | Needham | Buy |
| 2020-11-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-10-19 | Eingeleitet | Citigroup | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-08-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-08-18 | Eingeleitet | Needham | Buy |
| 2019-09-26 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-07-15 | Eingeleitet | BofA/Merrill | Neutral |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-07-15 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Personalis Inc Aktie (PSNL) Neueste Nachrichten
HC Wainwright Reaffirms Buy Rating for Personalis (NASDAQ:PSNL) - MarketBeat
Is a relief rally coming for Personalis Inc. holdersEarnings Beat & High Accuracy Swing Trade Signals - Newser
Personalis Inc. stock trend outlook and recovery pathMarket Sentiment Report & Consistent Income Trade Recommendations - Newser
How to build a dashboard for Personalis Inc. stockQuarterly Portfolio Summary & Weekly High Potential Alerts - Newser
Trexquant Investment LP Raises Stock Position in Personalis, Inc. $PSNL - MarketBeat
Will Personalis Inc. bounce back from current supportJuly 2025 News Drivers & Weekly Breakout Opportunity Watchlist - Newser
Can Personalis Inc. recover in the next quarter2025 Year in Review & Fast Entry and Exit Trade Plans - Newser
Ranking Personalis Inc. among high performing stocks via toolsQuarterly Investment Review & Fast Moving Trade Plans - Newser
Custom watchlist performance reports with Personalis Inc.Portfolio Risk Summary & AI Powered Market Trend Analysis - Newser
Is Personalis Inc. stock poised for growth2025 Dividend Review & Reliable Breakout Stock Forecasts - Newser
Personalis' MRD Breakthrough Potential: Why I Hold Until Reimbursement Clarity Emerges - Seeking Alpha
CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test - Business Wire
Recent Uptick Might Appease Personalis, Inc. (NASDAQ:PSNL) Institutional Owners After Losing 6.6% Over the Past Year - 富途牛牛
Is Personalis (NASDAQ:PSNL) A Risky Investment? - simplywall.st
Advanced analytics toolkit walkthrough for Personalis Inc.Weekly Risk Summary & Daily Price Action Insights - Newser
Signal strength of Personalis Inc. stock in tech scannersTrade Ideas & Technical Pattern Based Signals - Newser
Can a trend reversal in Personalis Inc. lead to recoveryTreasury Yields & Weekly Chart Analysis and Trade Guides - Newser
Is Personalis Inc. stock ready for a breakoutPortfolio Risk Summary & Real-Time Market Trend Scan - Newser
Momentum divergence signals in Personalis Inc. chartWeekly Profit Report & Weekly Breakout Opportunity Watchlist - Newser
H.C. Wainwright reiterates Buy rating on Personalis stock at $8.50 By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Buy rating on Personalis stock at $8.50 - Investing.com
PSNL: HC Wainwright Reiterates 'Buy' Rating and Maintains Price Target | PSNL Stock News - GuruFocus
What recovery options are there for Personalis Inc.Portfolio Profit Report & Smart Allocation Stock Tips - Newser
What are Personalis Inc.’s recent SEC filings showingEarnings Recap Report & Smart Money Movement Alerts - beatles.ru
Can Personalis Inc. expand its profit marginsJuly 2025 Intraday Action & Stepwise Swing Trade Plans - 강소기업뉴스
Is Personalis Inc. showing signs of accumulation2025 Trading Recap & Capital Efficiency Focused Ideas - Newser
Will Personalis Inc. stock go up in YEARQuarterly Earnings Summary & AI Driven Stock Price Forecasts - خودرو بانک
Personalis, Inc. shares rise 1.38% intraday after BioNTech's breast cancer trial win. - AInvest
Chart based exit strategy for Personalis Inc.Portfolio Performance Summary & Free Long-Term Investment Growth Plans - Newser
Can Personalis Inc. benefit from deglobalizationJuly 2025 Patterns & Growth Oriented Trade Recommendations - خودرو بانک
Long term hold vs stop loss in Personalis Inc.July 2025 Patterns & AI Powered Market Entry Strategies - Newser
Does Personalis Inc. have declining or rising EPSTrade Volume Report & Growth-Oriented Investment Plans - خودرو بانک
Personalis MRD test predicts outcomes in lung cancer trial By Investing.com - Investing.com Australia
Personalis, Inc. shares rise 1.03% premarket after announcing new data from AstraZeneca phase 3 clinical trial. - AInvest
Is Personalis Inc. stock a good pick for beginnersEarnings Recap Summary & Weekly Hot Stock Watchlists - خودرو بانک
Using R and stats models for Personalis Inc. forecasting2025 Top Gainers & AI Enhanced Execution Alerts - Newser
Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing - biospace.com
Will Personalis Inc. stock go up soonWeekly Earnings Recap & Verified Short-Term Plans - Newser
Personalis and the MRD Testing Revolution in Early-Stage Lung Cancer - AInvest
Personalis announces new data from neoadjuvant lung cancer trial - MarketScreener
Personalis reports data from lung cancer trial (PSNL:NASDAQ) - Seeking Alpha
Personalis MRD test predicts outcomes in lung cancer trial - Investing.com
Is Personalis Inc. reversing from oversold territoryTrade Performance Summary & Detailed Earnings Play Alerts - Newser
Is Personalis Inc. benefiting from interest rate changes2025 Market Trends & Reliable Price Action Trade Plans - خودرو بانک
Full technical analysis of Personalis Inc. stockQuarterly Performance Summary & Scalable Portfolio Growth Ideas - Newser
Finanzdaten der Personalis Inc-Aktie (PSNL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Personalis Inc-Aktie (PSNL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Tachibana Aaron | CFO AND COO |
Jul 28 '25 |
Sale |
6.57 |
641 |
4,211 |
164,458 |
| Tachibana Aaron | CFO AND COO |
May 16 '25 |
Sale |
4.95 |
1,291 |
6,390 |
165,099 |
| Moore Stephen Michael | SVP and Chief Legal Officer |
May 16 '25 |
Sale |
4.95 |
1,675 |
8,291 |
64,200 |
| Chen Richard | CHIEF MEDICAL OFFICER AND EVP |
May 16 '25 |
Sale |
4.95 |
910 |
4,504 |
124,957 |
| Tachibana Aaron | CFO AND COO |
Jan 28 '25 |
Sale |
5.79 |
708 |
4,099 |
166,390 |
| Chen Richard | CHIEF MEDICAL OFFICER AND EVP |
Jan 28 '25 |
Sale |
5.79 |
519 |
3,005 |
123,367 |
| Chen Richard | CHIEF MEDICAL OFFICER AND EVP |
Dec 16 '24 |
Sale |
3.82 |
4,834 |
18,466 |
123,886 |
| Moore Stephen Michael | SVP and Chief Legal Officer |
Dec 16 '24 |
Sale |
3.82 |
1,513 |
5,780 |
65,875 |
| Tachibana Aaron | CFO AND COO |
Dec 16 '24 |
Sale |
3.82 |
6,865 |
26,224 |
167,098 |
| Tachibana Aaron | CFO AND COO |
Nov 18 '24 |
Sale |
3.79 |
1,307 |
4,954 |
173,963 |
2.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):